Paediatric cancer drug shows 93% response rate
A first-of-its-kind drug, designated as 'breakthrough therapy' by the FDA, was effective in 93% of paediatric patients tested. Unlike most cancer drugs targeted to specific organs or locations in the body, Larotrectinib is for patients with a specific two-gene fusion in the cancer cell, regardless of cell type. Every patient treated in this study reported a decrease in tumour size.